Superbugs: How India's Wockhardt Cracked the Antibiotic Crisis

Summary

Imagine a world where a simple cut could be fatal, a reality before penicillin revolutionized human life expectancy from 40 to 70 years. Today, Alexander Fleming's warning about antibiotic misuse has become a crisis: multi-drug resistant bacteria, or superbugs, cause nearly 5 million deaths annually. This is driven by taking antibiotics unnecessarily, stopping courses early, or their widespread use in animal farming, essentially training bacteria to become stronger. Compounding this, major pharmaceutical companies have largely abandoned antibiotic research due to poor economics: high development costs of over $1.1 billion, low returns, and rapid obsolescence due to resistance and generic competition. However, Indian company Wockhardt is a beacon of hope. They invested $800 million from their stable insulin business over 30 years to develop six novel antibiotics, including the drug Zenic, targeting the deadliest superbugs. This groundbreaking research has created a drug valued at $9 billion, potentially securing a 15-year monopoly, and demonstrates the power of R&D, venturing into neglected markets, and funding bold bets with stable income.